Cargando…

Nesidioblastosis: an uncommon complication seen post Roux-en-Y gastric bypass

SUMMARY: Adult-onset nesidioblastosis is a rare complication of Roux-en-Y gastric bypass surgery and may occur months to years after the initial surgical procedure. It is manifested by a hyperinsulinemic, hypoglycemic state. The annual incidence of adult-onset hyperinsulinemic hypoglycemia is believ...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kiveum, Greenspan, Jacob Lim, Mehrara, Shaheen, Wynne, David, Ennis, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875027/
https://www.ncbi.nlm.nih.gov/pubmed/36571473
http://dx.doi.org/10.1530/EDM-22-0361
_version_ 1784877871159836672
author Kim, Kiveum
Greenspan, Jacob Lim
Mehrara, Shaheen
Wynne, David
Ennis, Elizabeth
author_facet Kim, Kiveum
Greenspan, Jacob Lim
Mehrara, Shaheen
Wynne, David
Ennis, Elizabeth
author_sort Kim, Kiveum
collection PubMed
description SUMMARY: Adult-onset nesidioblastosis is a rare complication of Roux-en-Y gastric bypass surgery and may occur months to years after the initial surgical procedure. It is manifested by a hyperinsulinemic, hypoglycemic state. The annual incidence of adult-onset hyperinsulinemic hypoglycemia is believed to be less than 0.1 in 1 000 000 with a mean age of onset of 47 years (1). Here, we describe a patient who presented with worsening hypoglycemic symptoms for 1 year prior to presentation that eventually progressed to hypoglycemic seizures. The onset of this hypoglycemia was 5 years after Roux-en-Y gastric bypass surgery. A full neurological evaluation, which included an EEG, head CT, and MRI, was performed to rule out epilepsy and other seizure-related disorders. After hypoglycemia was confirmed, extensive laboratory studies were obtained to elucidate the cause of the hypoglycemia and differentiate nesidioblastosis from insulinoma. Once the diagnosis of nesidioblastosis was established, a sub-total pancreatectomy was performed, and the patient was discharged and placed on acarbose, a competitive reversible inhibitor of pancreatic α-amylase and intestinal brush border α-glucosidases which slows carbohydrate absorption. The lack of information and understanding of nesidioblastosis due to its rarity makes any knowledge of this rare but important surgical complication essential. As incidence of obesity increases, the number of gastric bypasses being performed increases with it, and understanding this disease process will be essential for the primary care provider. This is the primary reason for the writing of this publication. LEARNING POINTS: Nesidioblastosis is a persistent hyperinsulinemic, hypoglycemic state, mostly seen after Roux-en-Y gastric bypass surgery, with symptoms occurring postprandially. The incidence is 0.1–0.3% of all post Roux-en-Y gastric bypass patients. The key diagnostic clue to identifying nesidioblastosis is a positive selective arterial calcium stimulation test, showing a diffuse pattern of increased basal hepatic venous insulin concentration, whereas insulinomas would show focal increases. Pathological specimen of pancreas will show diffuse hypertrophy of beta cells. Management includes acarbose and total or subtotal pancreatectomy, which can be curative. With the prevalence of obesity increasing and more patients turning to Roux-en-Y gastric bypass, more patients may be at risk of this potential surgical complication.
format Online
Article
Text
id pubmed-9875027
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-98750272023-02-06 Nesidioblastosis: an uncommon complication seen post Roux-en-Y gastric bypass Kim, Kiveum Greenspan, Jacob Lim Mehrara, Shaheen Wynne, David Ennis, Elizabeth Endocrinol Diabetes Metab Case Rep New Disease or Syndrome: Presentations/Diagnosis/Management SUMMARY: Adult-onset nesidioblastosis is a rare complication of Roux-en-Y gastric bypass surgery and may occur months to years after the initial surgical procedure. It is manifested by a hyperinsulinemic, hypoglycemic state. The annual incidence of adult-onset hyperinsulinemic hypoglycemia is believed to be less than 0.1 in 1 000 000 with a mean age of onset of 47 years (1). Here, we describe a patient who presented with worsening hypoglycemic symptoms for 1 year prior to presentation that eventually progressed to hypoglycemic seizures. The onset of this hypoglycemia was 5 years after Roux-en-Y gastric bypass surgery. A full neurological evaluation, which included an EEG, head CT, and MRI, was performed to rule out epilepsy and other seizure-related disorders. After hypoglycemia was confirmed, extensive laboratory studies were obtained to elucidate the cause of the hypoglycemia and differentiate nesidioblastosis from insulinoma. Once the diagnosis of nesidioblastosis was established, a sub-total pancreatectomy was performed, and the patient was discharged and placed on acarbose, a competitive reversible inhibitor of pancreatic α-amylase and intestinal brush border α-glucosidases which slows carbohydrate absorption. The lack of information and understanding of nesidioblastosis due to its rarity makes any knowledge of this rare but important surgical complication essential. As incidence of obesity increases, the number of gastric bypasses being performed increases with it, and understanding this disease process will be essential for the primary care provider. This is the primary reason for the writing of this publication. LEARNING POINTS: Nesidioblastosis is a persistent hyperinsulinemic, hypoglycemic state, mostly seen after Roux-en-Y gastric bypass surgery, with symptoms occurring postprandially. The incidence is 0.1–0.3% of all post Roux-en-Y gastric bypass patients. The key diagnostic clue to identifying nesidioblastosis is a positive selective arterial calcium stimulation test, showing a diffuse pattern of increased basal hepatic venous insulin concentration, whereas insulinomas would show focal increases. Pathological specimen of pancreas will show diffuse hypertrophy of beta cells. Management includes acarbose and total or subtotal pancreatectomy, which can be curative. With the prevalence of obesity increasing and more patients turning to Roux-en-Y gastric bypass, more patients may be at risk of this potential surgical complication. Bioscientifica Ltd 2022-12-05 /pmc/articles/PMC9875027/ /pubmed/36571473 http://dx.doi.org/10.1530/EDM-22-0361 Text en © The authors https://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle New Disease or Syndrome: Presentations/Diagnosis/Management
Kim, Kiveum
Greenspan, Jacob Lim
Mehrara, Shaheen
Wynne, David
Ennis, Elizabeth
Nesidioblastosis: an uncommon complication seen post Roux-en-Y gastric bypass
title Nesidioblastosis: an uncommon complication seen post Roux-en-Y gastric bypass
title_full Nesidioblastosis: an uncommon complication seen post Roux-en-Y gastric bypass
title_fullStr Nesidioblastosis: an uncommon complication seen post Roux-en-Y gastric bypass
title_full_unstemmed Nesidioblastosis: an uncommon complication seen post Roux-en-Y gastric bypass
title_short Nesidioblastosis: an uncommon complication seen post Roux-en-Y gastric bypass
title_sort nesidioblastosis: an uncommon complication seen post roux-en-y gastric bypass
topic New Disease or Syndrome: Presentations/Diagnosis/Management
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875027/
https://www.ncbi.nlm.nih.gov/pubmed/36571473
http://dx.doi.org/10.1530/EDM-22-0361
work_keys_str_mv AT kimkiveum nesidioblastosisanuncommoncomplicationseenpostrouxenygastricbypass
AT greenspanjacoblim nesidioblastosisanuncommoncomplicationseenpostrouxenygastricbypass
AT mehrarashaheen nesidioblastosisanuncommoncomplicationseenpostrouxenygastricbypass
AT wynnedavid nesidioblastosisanuncommoncomplicationseenpostrouxenygastricbypass
AT enniselizabeth nesidioblastosisanuncommoncomplicationseenpostrouxenygastricbypass